Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis

• Autori principali: Michael J. Cork (Autore), Diamant Thaçi (Autore), Lawrence F. Eichenfield (Autore), Peter D. Arkwright (Autore), Zhen Chen (Autore), Ryan B. Thomas (Autore), Matthew P. Kosloski (Autore), Ariane Dubost-Brama (Autore), Randy Prescilla (Autore), Ashish Bansal (Autore), Noah A. Levit (Autore)
• Natura: Libro
• Pubblicazione: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Background For children aged 6-11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to info...